#ACR23 Abstr#2576 Promising therapy in Dermatomyositis. Phase 2 RCT showed rapid improvement in skin, muscle & patient reported outcomes as fast as Week 4 in PF-06823859 (anti-IFN-B) vs PBO. Could be useful to treat in either skin or muscle predominant patients @RheumNow #ACRBest https://t.co/Rj1k1z0Tsz

L20 @ #ACR23 New therapy on the horizon for RA pts that failed MTX? ⭐️Telitacicept = recombinant fusion protein targeting & neutralizing BLyS & APRIL ➡️ placebo-controlled, phase III trial, 24w 👉at wk 24, PBO pts switched to drug arm for 24 more wks ➡️ 479 pts w/… https://t.co/94MyC8sdaG https://t.co/x3MUmFJPK6

What happens when you stop #steroids and/ immunosuppressive Rx in Pts in remission for at least 1 yr in #IgG4 disease? You are likely guessing correctly Pts flare! Don’t stop Rx ?taper 🤷‍♀️ Like RA Rx - if stop Rx = flares Large RCT from China L16 #ACR23 @RheumNow @RheumNow

#IA Injection in #knee #OA. TLC599 vs #dexamethasone vs saline #RCT-blinded. Both active #Rx better than #PBO. Some differences in average daily pain between active drugs. Not sure where it may fit in? After IA steroid failure? L18 #ACR23 ⁦@ACRheum⁩ ⁦@RheumNow⁩ https://t.co/rLh6ISBpUw

#ACR23 Abstr#2578 AI to phenotype sporadic IBM vs AI Myositis -Anti-NT5c1A assoc with dysphagia -Anti-Ro52/TRIM21: female -Anti-VCP: male -Anti-NT5c1A + clinical markers: high accuracy in separating SIBM vs AIM Need longitudinal data for clusters to be meaningful @RheumNow https://t.co/fu0a074XAZ

#ACR23 BEST Abstracts from San Diego – Day 1 From hundreds of online presentations, the poster floor and the plenary podium, here are some of the best abstracts from 11/12/23. You can spot these on Twitter by looking for the (#ACRbest) hashtag. https://t.co/h4RvFy66z9 https://t.co/LEhAUaw6Cj

• #ACR BEST Abstracts from San Diego – Day 1 | RheumNow